aiwiki.page
English
Health / Diseases & Symptoms / acute-chest-syndrome

Acute Chest Syndrome

Acute chest syndrome is a potentially life-threatening lung complication of sickle cell disease, characterized by a new pulmonary infiltrate and respiratory symptoms or fever.

24 keywords1 linked from3 not yet writtenWritten by AI
Sickle Cell Dise…FeverChest painCoughShortness of bre…SurgeryPneumoniaBone MarrowAcute Ches…

Acute chest syndrome (ACS) is an acute lung complication of sickle cell disease, defined by a new pulmonary infiltrate on chest imaging together with features such as fever, chest pain, cough, or shortness of breath. It can result from infection, obstruction of small pulmonary blood vessels, or fat embolization from damaged bone marrow, often with several mechanisms operating together. ACS is a major cause of hospitalization and death in people with sickle cell disease and can progress rapidly to respiratory failure.

Definition and clinical setting

A commonly used definition requires a new radiographic pulmonary infiltrate involving at least one lung segment, not explained solely by atelectasis, together with fever or a new respiratory symptom or sign. Atelectasis is incomplete expansion or collapse of part of the lung; although it does not alone satisfy this definition, it can contribute to the development of ACS.

ACS occurs in children and adults with different sickle cell genotypes. It is particularly associated with sickle cell anemia, including the HbSS genotype, but is not confined to that form of the disease. It may be the presenting reason for hospital admission or develop during hospitalization for a painful vaso-occlusive episode. It can also occur after surgery.

The term describes a clinical syndrome rather than a single cause. Infectious pneumonia and ACS are therefore not mutually exclusive diagnoses.

Causes and mechanisms

Several processes can initiate or amplify lung injury:

  • Infection. Respiratory viruses and bacteria can trigger pulmonary inflammation and sickling. An infectious organism is not identified in every episode.
  • Pulmonary microvascular obstruction. Sickled red blood cells and interactions among blood cells and the vessel lining can impair blood flow through the lungs.
  • Fat embolization. Injury and necrosis in bone marrow can release fat and marrow material into the circulation, producing pulmonary vascular obstruction and inflammation.
  • Reduced ventilation. Pain involving the chest wall, shallow breathing, and respiratory depression associated with sedating medicines can promote atelectasis and impaired oxygenation.

These mechanisms reinforce one another. Low oxygen levels promote polymerization of sickle hemoglobin, making red blood cells less deformable. Further obstruction, inflammation, and lung injury then worsen oxygenation. Hemolysis and dysfunction of the blood-vessel lining may also contribute.

Clinical features and severity

Typical features include fever, cough, rapid breathing, chest pain, and reduced blood oxygen saturation. Wheezing may occur. Children more often have prominent fever and cough, whereas adults are more likely to experience severe disease. Chest pain may be absent, so its absence does not exclude ACS.

The condition may evolve after an initially uncomplicated painful episode. Early chest radiographs can be unrevealing, with pulmonary changes becoming apparent later.

Severity ranges from a limited infiltrate with modest oxygen impairment to extensive lung involvement and respiratory failure. Findings associated with a more severe course include increasing oxygen requirements, multilobar infiltrates, a falling platelet count, and worsening anemia. Severe episodes can involve neurological abnormalities or failure of several organs.

Diagnosis and differential diagnosis

Diagnosis combines the clinical presentation with chest imaging. Assessment commonly includes:

  • Chest radiography to identify new pulmonary opacities.
  • Pulse oximetry to measure oxygen saturation, with blood-gas analysis in selected cases.
  • A complete blood count to assess hemoglobin, white blood cells, and platelets.
  • Microbiological investigations when infection is suspected.

No single laboratory test establishes the cause in all cases. A negative microbiological investigation does not exclude infection.

The differential diagnosis includes atelectasis, pulmonary edema, and pulmonary embolism. These conditions can also coexist with ACS. Computed tomography is not required for every episode, but CT pulmonary angiography may be used when pulmonary embolism is suspected.

Clinical management

ACS is managed as an acute hospital condition. Treatment addresses impaired oxygenation, possible infection, pain, and progression of sickle-related lung injury.

Supplemental oxygen is used for hypoxemia. Antibiotic treatment commonly covers typical and atypical respiratory bacteria because infectious and noninfectious causes are difficult to distinguish initially. Pain control supports breathing, while clinical monitoring addresses the possibility of excessive sedation and hypoventilation. Fluid management balances circulatory needs against the risk of worsening lung edema.

Incentive spirometry, which encourages sustained deep inspiration, is used to reduce atelectasis, particularly during admissions for painful episodes. Bronchodilators may be used when bronchospasm or coexisting asthma is present.

Blood transfusion can improve oxygen-carrying capacity and reduce the proportion of sickling red cells. Simple transfusion or red-cell exchange is selected according to disease severity, baseline hemoglobin, and clinical progression. Exchange transfusion removes circulating red cells while replacing them with donor cells and is used in severe or rapidly progressive disease. Respiratory support, including mechanical ventilation, may be necessary in respiratory failure.

Corticosteroids are not routine treatment for uncomplicated ACS because their use has been associated with rebound painful episodes and readmission, despite some evidence of shorter initial hospitalization.

Recurrence and prevention

ACS can recur. Previous episodes and asthma are associated with increased risk. Recurrent events can contribute to long-term pulmonary morbidity, although chronic lung dysfunction in sickle cell disease has multiple causes.

Hydroxyurea, a disease-modifying treatment that increases fetal hemoglobin, reduces ACS episodes in sickle cell anemia. Infection prevention, including appropriate vaccination, is part of broader sickle cell care. Regular transfusion programs are used in selected patients with recurrent severe complications, with their benefits weighed against risks such as iron overload and red-cell alloimmunization.